RhD-Alloimmunization in Adult and Pediatric Trauma Patients

Area of Science:

• Transfusion Medicine
• Immunology
• Trauma Care

Background:

• The transfusion of RhD-positive blood products to RhD-negative individuals can lead to alloimmunization, a significant concern in patient care.
• Current US standards of care lack specific guidance for RhD-typing transfusion decisions in trauma patients with unknown blood types, except for pregnant women and neonates.
• Reported alloimmunization rates range widely from 3% to 70%, indicating a need for clearer understanding in specific patient populations.

Purpose of the Study:

• To determine the prevalence of anti-D alloimmunization in RhD-negative trauma patients transfused with RhD-positive blood products.
• To synthesize existing evidence on RhD alloimmunization rates across different blood product types (whole blood, RBCs, platelets) in trauma settings.
• To identify factors influencing alloimmunization and highlight gaps in current transfusion guidelines for RhD-negative trauma patients.

Main Methods:

• A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
• Comprehensive database searches were conducted up to April 3, 2022, supplemented by additional relevant articles.
• Inclusion criteria focused on studies reporting anti-D alloimmunization prevalence in trauma patients receiving RhD-positive transfusions.

Main Results:

• The incidence of anti-D alloimmunization varied significantly: 7.8%–42.7% for whole blood, 0%–94% for red blood cells (RBCs), and 0%–19% for platelets.
• Alloimmunization rates increased with age, primarily detected in children over 5 years old.
• Existing guidelines recommend Rh immune globulin (RhIG) for pregnant trauma patients but lack specific guidance for non-pregnant RhD-negative individuals receiving RhD-positive components.

Conclusions:

• The prevalence of RhD alloimmunization in RhD-negative trauma patients is highly variable and influenced by numerous factors.
• There is a critical need for specific transfusion guidelines addressing RhD-incompatible transfusions in all RhD-negative trauma patients.
• Further research, potentially utilizing big data approaches, is essential for developing tailored transfusion strategies and understanding the role of RhIG in trauma settings.